Daily Archives: January 18, 2018

We recently described cobblestone (Cob) lesions in the ileum of SAMP1/YitFc (SAMP) mice, which is the only inbred mouse strain with polygenic predisposition to Crohn’s disease(CD)-like ileitis. Herein, we quantified the mRNA gene expression differenc… Continue reading →

Current guidelines endorsed by several societies suggest the use of spray chromoendoscopy (CE) to improve dysplasia detection during surveillance colonoscopy in patients with long standing IBD. Our goal was to compare dysplasia detection rates between … Continue reading →

Although traditional treatment algorithms for Crohn’s disease (CD) and ulcerative colitis (UC) are based on stepwise drug failure, pathways are shifting to a more individualized, risk-stratified approach. There is a perception that insurance policies may not have implemented this paradigm shift (1); particularly regarding access to vedolizumab (VDZ), an anti-α4β7 integrin antibody approved for the treatment of UC and CD. This study evaluated VDZ patient access by analyzing policy information from the Managed Markets Insight & Technology (MMIT) database (2). Continue reading →

IBD affects 1.6 million people in the US and is associated with increased healthcare utilization. Telemedicine is an alternative healthcare delivery system which could improve outcomes and decrease costs. The objective of this study was to compare heal… Continue reading →

Colorectal cancer (CRC) risk in patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC) is increased compared to the general population. The combination of IBD and PSC is associated with an increased risk for dysplasia a… Continue reading →

The similar presentations in relapse of inflammatory bowel disease (IBD) and enteric infection pose substantial barriers to diagnosis and treatment. The objective of this study was to investigate the endoscopic and histologic predictors of enteric infe… Continue reading →

Ulcerative colitis (UC) patients requiring colectomy often have a staged ileal pouch anal anastomosis (IPAA). There are no prospective data comparing timing of pouch creation. We aimed to compare 30-day adverse event (AE) rates for pouch creation at th… Continue reading →

Extraintestinal manifestations (EIMs) are common in Inflammatory bowel disease (IBD), adding to the burden of disease, with a prevalence varying from 6% to 46%. The mechanism of nephrolithiasis is different in Ulcerative Colitis (UC) and Crohn’s dise… Continue reading →

C. difficile infection (CDI) in Inflammatory bowel disease (IBD) is associated with poor outcomes. Fecal microbiota transplantation (FMT) is highly effective for recurrent CDI but data on outcomes of FMT for management of IBD are lacking. We report out… Continue reading →

Most Crohn’s Disease (CD) patients present with an inflammatory phenotype (B1), however, a subgroup rapidly progress to complicated disease behaviours such as stricturing (B2). Recent evidence suggests the involvement of gene-environmental interactio… Continue reading →